John Wilkerson is a Washington correspondent at RamaOnHealthcare. He covers a wide range of topics including health and wellness, government and politics, and the healthcare system, often focusing on public policy, consumer health, and pharmaceutical regulation. His work has been featured in STAT News and Daily Republic.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
John Wilkerson’s coverage predominantly focuses on healthcare and pharmaceuticals, with a strong emphasis on government announcements and legal policy regulations. Given this focus, he would likely be interested in receiving pitches from experts who can provide insights into the implications of new policies or regulatory changes within the healthcare and pharmaceutical sectors.
Given his interest in specific government actions related to drug pricing, FDA decisions, Medicare policies, and drug shortages, professionals with expertise in these areas may find success reaching out for commentary or analysis.
Wilkerson's US-based focus should be considered when pitching relevant stories or expert opinions tied to developments within the American healthcare system.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Save stories to read later, available anytime from your account.
By: John Wilkerson
Save stories to read later, available anytime from your account.
By: John Wilkerson
Rep. Jake Auchincloss (D-Mass.) has some advice for fellow lawmakers: unapologetically support the biotech industry, vilify insurance companies, and focus on making America a biotech research haven, instead of relying on protectionism.
By: John Wilkerson
Save stories to read later, available anytime from your account.
Speaking on the economy, the vice president told a crowd in Ohio that, “You don't turn the Titanic around overnight.” Send news tips and bad metaphors to [email protected] or John_Wilkerson.07 on Signal.
By: John Wilkerson
Rumors are swirling that the Treasury Department this week is going to propose a rule that restricts U.S. investment in the Chinese biotech sector.
By: Meghana Keshavan, John Wilkerson
Moderna and Merck's ESMO upcoming data, GLP-1s for addiction treatment, and more biotech news Want to stay on top of the science and politics driving biotech today?
By: John Wilkerson, Damian Garde
Save stories to read later, available anytime from your account.
By: Damian Garde, John Wilkerson
The proposal is more aggressive than anticipated, but it could change
Save stories to read later, available anytime from your account.
